ondansetron has been researched along with Argentaffinoma in 2 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ishizuka, J | 1 |
| Hsieh, AC | 1 |
| Townsend, CM | 1 |
| Thompson, JC | 1 |
| Jacobsen, MB | 1 |
2 other studies available for ondansetron and Argentaffinoma
| Article | Year |
|---|---|
Effect of 5-HT3 receptor antagonist (ondansetron) on functioning human pancreatic carcinoid cells.
Topics: Calcium; Carcinoid Tumor; Cell Division; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Hydro | 1993 |
Ondansetron in carcinoid syndrome.
Topics: Aged; Carcinoid Tumor; Humans; Imidazoles; Male; Ondansetron; Pancreatic Neoplasms; Serotonin Antago | 1992 |